medigraphic.com
ISSN 1029-3019 (Electronic)

2012, Number 11

<< Back Next >>

MediSan 2012; 16 (11)

Effectiveness of the Heberprot-P® in the treatment of diabetic foot ulcers

Rodríguez FZ, Wendy G, Matos TME, Romero GLI, Mustelier FHL

Language: Spanish
References: 25
Page: 1707-1711
PDF size: 187.11 Kb.


ABSTRACT

A descriptive and cross-sectional study was conducted in 120 patients with diabetic foot ulcers treated at "El Bajo" Comprehe nsive Diagnosis Center belonging to San Francisco municipality, Maracaibo, State of Zulia, Bolivarian Republic of Venezuela, from February 2011 to February 2012 in or der to evaluate the effectiveness of the administration of human epidermal growth factor. Age group of 55-59 years and the females prevailed in the case material. In all patients of the series granulation and healing of lesions was obtained and amputation was not necessary. Intralesional administration of Heberprot-P® can complete closure of the lesion; therefore it is a safe and advisable drug to heal these ulcers.


REFERENCES

  1. Perich Amador P, González Suárez RM, Valdés Ramos E, Arranz Calzado MC. Desarrollo de diabetes mellitus en pacientes con tolerancia a la glucosa alterada: seguimiento de 18 años. Rev Cubana Endocrinol. 2002 [citado 22 May 2012]; 13(2). Disponible en: http://www.bvs.sld.cu/revistas/end/vol13_2_02/end02202.htm

  2. Berlanga J, Cibrian D, Guillén I, Freyre F, Alba JS, López –Saura P, et al. Methylglyoxal administration induces diabetes-like microvascular changes and perturbs the healing process of cutaneous wounds. Clin Sci (Lond). 2005; 109(1):83-95.

  3. Portero-Otín M, Pamplona R, Bellmunt MJ, Ruiz MC, Prat J, Salvayre R, et al. Advanced glycation end product precursors impair epidermal growth factor receptor signaling. Diabetes. 2002; 51:1535-42.

  4. Berlanga J, Prats P, Ramirez D, Gonzalez R, Lopez-Saura P, Aguiar J, et al. Prophylactic use of epidermal growth factor reduces ischemia /reperfusion intestinal damage. Am J Pathol. 2002; 161(2):373-9.

  5. Steed DL. Clinical evaluation of recombinant human platelet–derived growth factor for the treatment of lower extremity ulcers. Plats Reconstruct Surg. 2006; 117 (7 Suppl): 143-9.

  6. American Diabetes Association: clinical practice recommendations 1997. Diabetes Care. 1997; 20 (Suppl 1):1-70.

  7. Foot Care in patients with diabetes mellitus. Diabetes Care. 1992 [citado 22 May 2012]; 15(Supp 2). Disponible en: http://care.diabetesjournals.org/content/15/Supplement_2/19.full.pdf

  8. Aragón J, Ortiz P, Hernández M. El pie diabético: resultados de nuestra experiencia. Aten Primaria. 1998; 22:369.

  9. Aragón Sánchez FJ, Hernández MJ, Ortiz PP. Claves para un diagnóstico y tratamiento adecuados. FOMECO. 2000; 8: 10-25.

  10. Guirao AA, Yuste SR, Regueiro BJ. Epidemiología y manifestaciones clínicas de las hepatitis virales. Enf Infecc Microbiol Clin. 2006; 24:264-76.

  11. Patel K, Muir AJ, Mc Hutchison JG. Diagnosis and treatment of chronic hepatitis C infection. BMJ. 2006; 332:1013-17.

  12. Hughes CA, Shafran SD. Chronic hepatitis C virus management: 2000-2005 update. Ann Pharmacother. 2006; 40(1):74-82.

  13. Valtiville R, Moretto H, Lef l. Decline of high hepatitis c. Virus prevalence in a hemodyalisis unit with isolation measures during a 6- year follow up. Clin Nephrol. 2002; 57:371-5.

  14. Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci. 2006; 3:47-52.

  15. Narasimhan G, Sargios TN, Kalakuntla R, Homel P, Clain DJ, Theise ND, et al. Treatment rates in patients with chronic hepatitis C after liver biopsy. J Viral Hepat. 2006; 13(11):783-6.

  16. World Health Organization. Hepatitis C [citado 12 May 2011]. Disponible en: http://www.who.int/csr/disease/hepatitis/Hepc.pdf

  17. Asian Pacific Association for the Study of the Liver (APASL), Hepatitis C Working Party, McCaughan GW, Omata M, Amarapurkar D, Bowden S, et al. Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol. 2007; 22(5):615-33.

  18. Bruguera M, Forns X. Hepatitis C en España. Med Clin (Barc). 2006; 127:113-7.

  19. Harris HE, Eldridge KP, Harbour S, Alexander G, Teo CG, Ramsay ME, et al. Does the clinical outcome of hepatitis C infection vary with the infecting hepatitis C virus type? J Viral Hepat. 2007; 14(3):213-20.

  20. Programa hemoterapia, banco de sangre PRONAHEBAS, seroprevalencia a marcadores serológicos de hepatitis viral en donantes de sangre. Informe anual. Lima: MINSA; 2000.

  21. Sanchez JL, Sjogren MH, Callahan JD, Watts DM, Lucas C, Abdel-Hamid M, et al. Hepatitis C in Peru: risk factors for infection, potential iatrogenic transmission, and genotype distribution. Am J Trop Med Hyg. 2000; 63(5-6): 242-8.

  22. Pawlotsky JM. Pathophysiology of hepatitis C virus infection and related liver disease. Trends Microbiol. 2004; 12:96-102.

  23. Sansonno D, Dammacco F. Hepatitis C virus, cryoglobulinaemia and vasculitis: immune complex relations. Lancet Infect Dis. 2005; 5:227-36.

  24. Fabrizi F, Martin P, Dixit V, Bresina M, Russell J, Conrad A, et al. Detection of de novo hepatitis C virus infection by polymerase chain reaction in hemodialysis patients. Am J Nephrol. 1999; 19(3):383-8.

  25. Di Lallo D, Miceli M, Petrosillo N, Perucci CA, Moscatelli M. Risk factors of hepatitis C virus infection in patients on hemodialysis. A multivariate analysis based on a dialysis register in Central Italy. Eur J Epidemiol 1999; 15(1)11-14.




2020     |     www.medigraphic.com